The Journal of Rheumatology

VOLUME 43: NO. 9 jrheum.org SEPTEMBER 2016

Editorial

A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?
D. Launay 1619

Articles

Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with RA
E. Ikdahl, S. Rollefstad, G. Wibetoe, et al 1622

ACR/EULAR Definitions of Remission Are Associated with Lower Residual Inflammatory Activity Compared with DAS28 Remission on Hand MRI in RA
M.P. Lisbona, A. Solano, J. Ares, M. Almirall, T.C. Salman-Monte, J. Maymó 1631

Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active RA Despite MTX Therapy: Results of 2 Phase II Studies
R.L. Thurmond, A. Greenspan, W. Radziszewski, et al . . 1637

Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in RA: Results from an Australian Early Arthritis Cohort
N.T. Wabe, M.J. Sorich, M.D. Wechalekar, et al 1643

Infection in Southern Chinese Patients with SLE: Spectrum, Drug Resistance, Outcomes, and Risk Factors
D. Chen, J. Xie, H. Chen, et al 1650

Associations of the Levels of C4d-bearing Reticulocytes and High-avidity Anti-dsDNA Antibodies with Disease Activity in SLE
C. Mora, J. Medina-Rosas, A.M. Santos, et al 1657

The Recurrence of Digital Ulcers in Patients with SSc after Discontinuation of Oral Treprostinil
A.A. Shah, E. Schiopu, S. Chatterjee, et al 1665

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial *D. Khanna, C. Albera, A. Fischer, et al* 1672

The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis
M.J. Kviatkovsky, S. Ramiro, R. Landewé, et al 1680

Development of a Screening Tool for the Identification of Sacroiliitis in CT Scans of the Abdomen
J. Chan, I. Sari, D. Salonen, R.D. Inman, N. Haroon . . . 1687

Involvement of Mucosal-associated Invariant T cells in Ankylosing Spondylitis
E. Hayashi, A. Chiba, K. Tada, et al 1695

Serum CRP Levels Demonstrate Predictive Value for Radiographic and MRI Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab
J. Braun, X. Baraliakos, K.G. Hermann, S. Xu, B. Hsu 1704

Efficacy of Subcutaneous Secukinumab in Patients with Active PsA Stratified by Prior TNF Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study
A. Kavanaugh, I.B. McInnes, P.J. Mease, et al 1713

Attainment of Minimal Disease Activity Using MTX in PsA
B.J. Sheane, A. Thavaneswaran, D.D. Gladman, V. Chandran 1718

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with PsA: Results of the PALACE 2 Trial
M. Cutolo, G.E. Myerson, R.M. Fleischmann, et al 1724

Gottron Papules and Gottron Sign with Ulceration: A Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis
H. Cao, Q. Xia, M. Pan, et al 1735

Widespread Pain and Low Widespread Pain Index Scores among FM-positive Cases Assessed with the 2010/2011 FM Criteria
F. Wolfe, N. Egloff, W. Häuser 1743

The Effect of the Presence of FM on Common Clinical Disease Activity Indices in Patients with PsA: A Cross-sectional Study
S. Brikman, V. Furer, J. Wollman, et al 1749

Free online via JRheum Full Release option

Contents continued on page xii

PRINTED IN CANADA – ISSN 0315-162X

Downloaded on September 9, 2026 from www.jrheum.org

Pediatric Rheumatology

The Systemic JIA Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010–2013
G. Janow, L.E. Schanberg, S. Setoguchi, et al, and the CARRA Legacy Registry Investigators. 1755

Images in Rheumatology

Unilateral Macular Lymphocytic Arteritis
A. Arana-Guajardo, C. Mendoza-Rodríguez, I. Miranda-Maldonado 1763

Correspondence

Defining Low Disease Activity States in PsA Using Novel Composite Disease Instruments
E. Lubrano, F.M. Perrotta. 1765

Reply *L.C. Coates, P.S. Helliwell*. 1766

Mycophenolate Mofetil in Refractory Cutaneous Lupus Erythematosus: No Definitive Evidence
C. Bachmeyer, S. Galmiche, A. Fayand, A. Degachi, S. Georgin-Lavialle. 1766

Reply *K. Tselios, D.D. Gladman, J. Su, M.B. Urowitz*. . . . 1767

Letters

Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and SSc
L. Fotis, K.W. Baszis, A.J. White, A.R. French. 1768

Development of Nephrotic Syndrome in a Patient with RA Treated with Certolizumab
R.R. Butendieck Jr., T. Bhattacharya, X. Geiger 1770

Correction

Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study
E. Lubrano, F.M. Perrotta, M. Manara, et al. 1772

Meetings in Rheumatology x

Downloaded on September 9, 2026 from www.jrheum.org